Lata Jayaraman Email

EVP and Head Discovery & Translational Biology . LifeMine Therapeutics

Current Roles

Employees:
146
Revenue:
$28.3M
About
LifeMine Therapeutics is pioneering a genomically-enabled drug discovery approach integrating advanced life science and computational technologies to elucidate human biology and create sophisticated therapeutics that attack the fundamental drivers of serious human diseases. LifeMine will access new drug modalities by conducting the first industrial-scale operation exploiting small molecule evolution in fungi to discover game-changing therapeutics. The initial focus will be on immune modulators, metabolic effectors, and cell differentiators. This platform is expected to provide multiple first- and best-in-class therapeutics in succession, and to continue delivering these for years to come. Founder & CEO: Greg Verdine, Erving Professor at Harvard University and Harvard Medical School. Founder of Gloucester Pharmaceuticals (acquired by Celgene), Enanta Pharmaceuticals (NASDAQ: ENTA), Eleven Biotherapeutics (NASDAQ: EBIO), Tokai Pharmaceuticals (NASDAQ: TKAI), WaVe Life Sciences (NASDAQ: WVE), Warp Drive Bio, Aileron Therapeutics, and the non-profit Gloucester Marine Genomics Institute and Gloucester Biotechnology Academy.
LifeMine Therapeutics Address
30 Acorn Park Drive
Cambridge, MA
United States
LifeMine Therapeutics Email

Past Companies

LifeMine TherapeuticsExecutive Vice President and Head of Discovery & Translational Biology
Bristol-Myers SquibbExecutive Director and Head, Oncology Drug Discovery, Mechanisms of Cancer Resistance
Seres TherapeuticsSenior Director & Head, Tumor Immunotherapy

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.